吉利德公司开放标签严重患者试验：瑞德西韦5天和10天给药方案疗效相似
▎药明康德内容团队编辑
不同地域的患者的临床结果有别。在意大利以外的地区，第14天时两个治疗组综合的总死亡率为7%（23/320），64%（205/320）的患者获得临床康复，61%（196/320）的患者出院。
参考资料：
[1] Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases’ Study of Investigational Antiviral Remdesivir for COVID-19. Retrieved April 29, 2020, from https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-sciences-statement-on-positive-data-emerging-from-national-institute-of-allergy-and-infectious-diseases-study-of-investigational-antiviral-rem
[2] Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19. Retrieved April 29, 2020, from https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19
[3] The world wants answers on Gilead’s Covid-19 drug. Experts worry next studies may increase uncertainty. Retrieved April 29, 2020, from https://www.statnews.com/2020/04/27/the-world-wants-answers-on-gileads-covid-19-drug-experts-worry-next-studies-may-increase-uncertainty/
[4] NIH Clinical Trial of Remdesivir to Treat COVID-19 Begins. Retrieved April 29, 2020, from https://www.niaid.nih.gov/news-events/nih-clinical-trial-remdesivir-treat-covid-19-begins
版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。